玟均 施
0 followers · 881 views
on the atlas · 32
- Curius / Bookmarks for the extremely curious190 savers
- Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate | Blood | American Society of Hematology1 savers
- Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate - PMC1 savers
- HIV-related lymphomas: Primary central nervous system lymphoma - UpToDate1 savers
- HIV-related lymphomas: Primary central nervous system lymphoma - UpToDate1 savers
- Immune reconstitution inflammatory syndrome - UpToDate1 savers
- Clinical manifestations and diagnosis of Candida infection in neonates - UpToDate1 savers
- Genetic susceptibility to Candida infections - PMC1 savers
- Treatment of knee osteoarthritis with acupuncture combined with Chinese herbal medicine: a systematic review and meta-analysis - Yang - Annals of Palliative Medicine1 savers
- uveitic-macular-edema-a-stepladder-treatment-paradigm.pdf1 savers
- Uveitic Macular Edema - StatPearls - NCBI Bookshelf1 savers
- Varicella zoster virus-associated non-necrotizing retinitis: case report | Journal of Ophthalmic Inflammation and Infection | Full Text1 savers
- Varicella zoster virus-associated Chorioretinitis: a case report - PMC1 savers
- Eye and Periocular Skin Involvement in Herpes Zoster Infection - PMC1 savers
- Chorioretinitis - StatPearls - NCBI Bookshelf1 savers
- Herpes Zoster Ophthalmicus - StatPearls - NCBI Bookshelf1 savers
- Necrotizing and Nonnecrotizing Variants of Herpetic Uveitis With Posterior Segment Involvement | Ophthalmology | JAMA Ophthalmology | JAMA Network1 savers
- Recurrence characteristics and clinicopathological results of borderline ovarian tumors | BMC Women's Health | Full Text1 savers
- Borderline ovarian tumors - UpToDate1 savers
- Borderline ovarian tumors - UpToDate1 savers
- Scrub typhus: Treatment and prevention - UpToDate1 savers
- Scrub typhus: Clinical features and diagnosis - UpToDate1 savers
- Thyroid-associated Ophthalmopathy - PMC1 savers
- Thoracolumbar Spine Fracture - StatPearls - NCBI Bookshelf1 savers
- Spinal column injuries in adults: Definitions, mechanisms, and radiographs - UpToDate1 savers
- Clinical Outcomes of Arthroscopic Tenodesis Versus Tenotomy for Long Head of the Biceps Tendon Lesions: A Systematic Review and Meta-analysis of Randomized Clinical Trials and Cohort Studies - PMC1 savers
- Biceps Tendon Dislocation and Instability - StatPearls - NCBI Bookshelf1 savers
- Initial treatment of acute promyelocytic leukemia in adults - UpToDate1 savers
- Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults - UpToDate1 savers
- Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia - UpToDate1 savers
- Optimal timing for Soave primary pull-through in short-segment Hirschsprung disease: A meta-analysis ClinicalKey 臨床醫學資料庫3 savers
- Curius / Onboarding2704 savers
highlights · 565
The most common adverse events were hematologic, including grade 4 neutropenia, experienced by 83% of participants. Grade 4 leukopenia (42%) and CD4+ lymphopenia (33%) were also common, although CD4+ T cells increased overall throughout induction treatment. No participants developed opportunistic infections during therapy.
Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate | Blood | American Society of HematologyOverall, 8 (67%) of the 12 participants had a sustained CR, including 3 who received second-line therapy without relapse at 2 years (Figure 1).
Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate | Blood | American Society of HematologyThe primary objective was to estimate the percentage of participants who had neither recurrent lymphoma nor severe general cognitive dysfunction at 2 years.
Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate | Blood | American Society of HematologyAll participants received concurrent ART and appropriate antimicrobial prophylaxis.16 Induction treatment included rituximab (375 mg/m2) IV on day 1 followed by HD-MTX (6 g/m2) IV and leucovorin rescue beginning on day 2 every 2 weeks for 6 cycles.
Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate | Blood | American Society of HematologyBefore effective ART, the principal mode of treatment of HIV-PCNSL was palliative whole-brain radiotherapy, resulting in long-term neurotoxicity
Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate | Blood | American Society of Hematologytreatment with ART and rituximab plus HD-MTX is associated with a high response rate, CD4+ lymphocyte reconstitution, and long-term survival with preservation or improvement of neurocognitive function.
Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate | Blood | American Society of HematologyOur study is the first to prospectively evaluate the responses and long-term neurocognitive effects of radiation-sparing therapy in HIV-PCNSL
Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate | Blood | American Society of Hematologypercentage of participants who had neither recurrent lymphoma nor severe general cognitive dysfunction at 2 years.
Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate - PMCineligible to receive HD-MTX at enrollment received ART, rituximab, and best-available chemotherapy
Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate - PMCcomplete response (CR) received 2 consolidation cycles of rituximab plus HD-MTX
Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate - PMCAdults with HIV and pathologically confirmed primary CNS B-cell lymphoma
Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate - PMCInduction treatment included rituximab (375 mg/m2) IV on day 1 followed by HD-MTX (6 g/m2) IV and leucovorin rescue beginning on day 2 every 2 weeks for 6 cycles
Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate - PMCAll participants received concurrent ART and appropriate antimicrobial prophylaxis
Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate - PMCHigh-dose methotrexate (HD-MTX) with leucovorin rescue and rituximab is relatively nonmyelotoxic and has been used successfully in other HIV-associated lymphomas
Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate - PMCBefore effective ART, the principal mode of treatment of HIV-PCNSL was palliative whole-brain radiotherapy, resulting in long-term neurotoxicity
Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate - PMCOverall survival (OS) of patients with HIV-PCNSL before the advent of antiretroviral therapy (ART) was <2 months, and although OS has improved with ART-associated immune reconstitution, median OS is generally reported to be <1 year
Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate - PMCCD20+ and usually Epstein Barr virus (EBV)–positive B-cell lymphoproliferative disorders
Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate - PMCHigh-dose methotrexate
HIV-related lymphomas: Primary central nervous system lymphoma - UpToDatecontemporary combination antiretroviral therapy
HIV-related lymphomas: Primary central nervous system lymphoma - UpToDatehigh-dose intravenous methotrexate
HIV-related lymphomas: Primary central nervous system lymphoma - UpToDatesystemic therapy with adequate CNS penetration
HIV-related lymphomas: Primary central nervous system lymphoma - UpToDatemultifocal/disseminated disease within the CNS
HIV-related lymphomas: Primary central nervous system lymphoma - UpToDatetoxoplasmosis, progressive multifocal leukoencephalopathy (PML), cytomegalovirus (CMV) encephalitis, and other opportunistic infections, such as bacterial or fungal abscesses or, in the developing world, tuberculosis.
HIV-related lymphomas: Primary central nervous system lymphoma - UpToDatelow CD4 cell count (eg, <200 cells/microL)
HIV-related lymphomas: Primary central nervous system lymphoma - UpToDatechronic co-infection with hepatitis B and hepatitis C virus
HIV-related lymphomas: Primary central nervous system lymphoma - UpToDatelow CD4 count, high HIV viral load
HIV-related lymphomas: Primary central nervous system lymphoma - UpToDatediffuse large B cell lymphoma
HIV-related lymphomas: Primary central nervous system lymphoma - UpToDateAbsence of EBV-specific CD4+ T cell effector function
HIV-related lymphomas: Primary central nervous system lymphoma - UpToDateEpstein-Barr virus (EBV)
HIV-related lymphomas: Primary central nervous system lymphoma - UpToDateKaposi sarcoma, non-Hodgkin lymphoma (NHL) of high-grade pathologic type and of B cell or unknown immunologic phenotype, primary central nervous system lymphoma (PCNSL), and invasive cervical carcinoma
HIV-related lymphomas: Primary central nervous system lymphoma - UpToDate(CSF) of many patients by polymerase chain reaction (PCR)
HIV-related lymphomas: Primary central nervous system lymphoma - UpToDatehistopathologic specimens via in situ hybridization for EBV-encoded small nuclear RNA (EBER)
HIV-related lymphomas: Primary central nervous system lymphoma - UpToDateT cell effector function
HIV-related lymphomas: Primary central nervous system lymphoma - UpToDateAbsence of EBV-specific CD4+
HIV-related lymphomas: Primary central nervous system lymphoma - UpToDateEpstein-Barr virus (EBV) infection
HIV-related lymphomas: Primary central nervous system lymphoma - UpToDateCD4 count that is usually below 100 cells/microL
HIV-related lymphomas: Primary central nervous system lymphoma - UpToDateKaposi sarcoma, non-Hodgkin lymphoma (NHL) of high-grade pathologic type and of B cell or unknown immunologic phenotype, primary central nervous system lymphoma (PCNSL), and invasive cervical carcinoma.
HIV-related lymphomas: Primary central nervous system lymphoma - UpToDateparadoxical worsening of preexisting infectious processes following the initiation of antiretroviral therapy (ART) in HIV-infected individuals
Immune reconstitution inflammatory syndrome - UpToDateCandida endophthalmitis
Clinical manifestations and diagnosis of Candida infection in neonates - UpToDateCandida chorioretinitis (minimal or no vitreous inflammation) and endophthalmitis (marked vitritis)
Clinical manifestations and diagnosis of Candida infection in neonates - UpToDateimmaturity of their immune and host epithelial protection, compromise of their epithelial protection with invasive procedures (eg, intubation, central venous catheters, and/or surgery), and factors that promote increased density of candidal colonization (eg, administration of broad-spectrum antibiotics
Clinical manifestations and diagnosis of Candida infection in neonates - UpToDatepustules, vesicles, or even bullae
Clinical manifestations and diagnosis of Candida infection in neonates - UpToDategeneralized eruption of 2 to 4 mm erythematous macules and/or papules that rest upon a 5 to 10 mm erythematous base.
Clinical manifestations and diagnosis of Candida infection in neonates - UpToDatesystemic dissemination is greatest among ELBW infants
Clinical manifestations and diagnosis of Candida infection in neonates - UpToDateascending infection is increased by ruptured membranes, presence of a uterine or cervical foreign body, and a history of vaginal candidiasis
Clinical manifestations and diagnosis of Candida infection in neonates - UpToDatein utero or during delivery
Clinical manifestations and diagnosis of Candida infection in neonates - UpToDateextremely low birth weight
Clinical manifestations and diagnosis of Candida infection in neonates - UpToDatean area of confluent erythema in the inguinal region, discrete erythematous papules and plaques with superficial scales, and satellite lesions
Clinical manifestations and diagnosis of Candida infection in neonates - UpToDateirregular white plaques with or without an erythematous base on the buccal or lingual mucosal surface of the mouth
Clinical manifestations and diagnosis of Candida infection in neonates - UpToDateMaternal vaginal colonization with Candida
Clinical manifestations and diagnosis of Candida infection in neonates - UpToDate